![]() ![]() Chartwell Investment Partners LLC Reduces Stock Position in Seagate Technology Holdings plc (NASDAQ:STX).Weyerhaeuser (NYSE:WY) Shares Sold by Chartwell Investment Partners LLC.Chartwell Investment Partners LLC Raises Position in Roche Holding AG (OTCMKTS:RHHBY).(NYSE:TFC) Shares Sold by Chartwell Investment Partners LLC (NYSE:MLM) Position Trimmed by Chartwell Investment Partners LLC Diversified Trust Co Reduces Position in The Mosaic Company (NYSE:MOS).Mirador Capital Partners LP Has $1.02 Million Holdings in Cisco Systems, Inc.(NASDAQ:INTC) Shares Sold by Raymond James & Associates HB Wealth Management LLC Buys 243 Shares of iShares MSCI USA Quality Factor ETF (BATS:QUAL).Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with 's FREE daily email newsletter. was incorporated in 2015 and is headquartered in Redwood City, California. and changed its name to Bolt Biotherapeutics, Inc. The company was formerly known as Bolt Therapeutics, Inc. Hoffmann-La Roche Ltd and license agreement with Stanford University. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. It is also developing BDC-2034, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company's lead product candidate BDC-1001, which is in Phase II clinical trial for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. ![]() About Bolt Biotherapeuticsīolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer. was incorporated in 2009 and is headquartered in South San Francisco, California. and changed its name to Unity Biotechnology, Inc. The company was formerly known as Forge, Inc. It also develops UBX1967 for the treatment of ophthalmologic diseases UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. ![]() This table compares Unity Biotechnology and Bolt Biotherapeutics’ net margins, return on equity and return on assets.īolt Biotherapeutics beats Unity Biotechnology on 8 of the 14 factors compared between the two stocks. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Comparatively, 28.4% of Bolt Biotherapeutics shares are owned by insiders. 4.9% of Unity Biotechnology shares are owned by insiders. Comparatively, 68.8% of Bolt Biotherapeutics shares are owned by institutional investors. Institutional and Insider OwnershipĢ4.2% of Unity Biotechnology shares are owned by institutional investors. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Unity Biotechnology, indicating that it is currently the more affordable of the two stocks. Unity Biotechnology has higher earnings, but lower revenue than Bolt Biotherapeutics. ![]()
0 Comments
Leave a Reply. |